Proliferating cells, in particular tumor cells, express a dimeric isoenzyme of pyruvate kinase, termed Tumor M2 pyruvate kinase. In the last few years, much attention has been paid to this novel tumor ...

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare ...

(RTTNews) - Agios Pharmaceuticals Inc. (AGIO), said on Friday that the FDA has approved Pyrukynd for the treatment of hemolytic anemia in adults with pyruvate kinase or PK deficiency, a rare, ...

(RTTNews) - Agios Pharmaceuticals, Inc. (AGIO) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion on ...

We show that the M2 isoform of pyruvate kinase (M2PYK) exists in equilibrium between monomers and tetramers regulated by allosteric binding of naturally occurring small-molecule metabolites.

Lung cancer, notorious for its high mortality rates, is a leading cause of cancer-related deaths globally, with metastasis being the primary contributor to poor patient outcomes. A critical factor in ...

Lei Wang, Jun Young Park, Fengming Liu, Kris M. Olesen, Shirui Hou, Jamy C. Peng, Jordan Infield, Anna C. Levesque, Yong-Dong Wang, Hongjian Jin, Yiping Fan, Patrick ...

Tumor M2-PK is becoming established as a good noninvasive screening option for colorectal cancer with a reported sensitivity between 68.8 and 91.0% and an overall specificity ranging from 71.9 to 100% ...